Dr Victor R Risch, MD | |
Cedar Crest I78, Allentown, AL 18105 | |
(610) 402-0700 | |
Not Available |
Full Name | Dr Victor R Risch |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | Cedar Crest I78, Allentown, Alabama |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1811970296 | NPI | - | NPPES |
01222901 | Other | PA | CAPITAL BC |
016914 | Other | PA | BCBS PA |
P2821009 | Other | PA | OXFORD |
300018185 | Other | PA | RAILROAD MEDICARE |
34109 | Other | PA | GEISINGER HEALTH PLAN |
20010565 | Other | PA | AMERIHEALTH MERCY |
0011264370007 | Medicaid | PA | |
0016914 | Other | PA | KEYSTONE HEALTHPLAN CENTR |
0071398000 | Other | PA | KEYSTONE HEALTH PLAN EAST |
133200 | Other | PA | MEDPLUS/THREE RIVERS |
6123250002 | Other | PA | CIGNA HMO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2085R0001X | Radiology - Radiation Oncology | MD025945E (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Victor R Risch, MD 1020a E Boal Ave, Boalsburg, PA 16827-1509 Ph: (814) 237-8627 | Dr Victor R Risch, MD Cedar Crest I78, Allentown, AL 18105 Ph: (610) 402-0700 |
News Archive
Researchers at the University at Buffalo have discovered a previously unknown neural pathway that can regulate changes made in the brain due to cocaine use, providing new insight into the molecular basis of cocaine addiction.
Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester's registration study in cutaneous T-cell lymphoma (CTCL) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.
Merck & Co., Inc. announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.
Griffith University psychologists have co-authored a book designed to fill a much-needed gap in assisting families where one child has suffered a sudden brain injury.
› Verified 1 days ago